2nd ICPerMed Workshop: Personalised Medicine for All Citizens and Patients within Sustainable Implementation

Plenary Session 2.2. Introduction of the Working Groups’ Panels

Maria Cristina Nieto Garcia

National Health School, National Institute of Health Carlos III (ISCIII), Madrid, Nov 5-6

Horizon 2020

GRANT AGREEMENT
NUMBER — 731366 — ICPerMed Secretariat
Workshop Working Group I

*Personalised Medicine (PM): How to ensure awareness and empowerment for all citizen’s?*

- **Chair:** Dr Sabrina Montante (National Institute of Health of Italy/ ISS, Italy)

- **Vice-chair:** Dr Marta Puyol Escolar (Spanish Association Against Cancer Scientific Foundation/ AECC-FC, Spain)

- **Rapporteur:** Dr Terje Peetso (North Estonia Medical Centre/ NEMC, Estonia)

- **Vice-rapporteur:** Pepa López (National Institute of Health Carlos III, Spain)
**Workshop Working Group I**  
*Personalised Medicine (PM): How to ensure awareness and empowerment for all citizens?*

**Leading questions:**

1. Role of (digital) health literacy in patient empowerment.
2. Transformation of the role of the patient towards the disease through data management.
3. Patient and public engagement with their health services.
Workshop Working Group II
Which are the Ethical, Legal and Social Implications (ELSI) of Personalised Medicine (PM) research and implementation?

• Chair: Prof. Dr. Anne Cambon-Thomsen (Inserm & University of Toulouse III, France)

• Vice-chair: Prof. Dr. Gaetano Guglielmi (Italian Ministry of Health, Italy)

• Rapporteur: Prof. Dr. Eva Winkler (University of Heidelberg, Germany)

• Vice-rapporteur: Candi Sánchez (National Institute of Health Carlos III, Spain)
Workshop Working Group II
Which are the Ethical, Legal and Social Implications (ELSI) of Personalised Medicine (PM) research and implementation?

Leading questions:

1. The handling of incidental/ additional findings originating from molecular analysis.
2. Informing the patient adequately about the tension between data-provision and the protection of a person’s privacy.
3. The tension between principles of evidence-based medicine and fast translation.
Workshop Working Group III

Transfer of research results into the market: How to optimize a safe, fast and economic process to implement Personalised Medicine (PM) approaches?

- **Chair:** Dr. Anna Rita Franco Migliaccio (University of Bologna, Italy)

- **Vice-chair:** Dr. Sebastian Delbrück (VDI/VDE Innovation + Technik GmbH, Germany)

- **Rapporteur:** Prof Dr. Jacques Demotes (ECRIN, France)

- **Vice-rapporteur:** Ignacio Baanante (National Institute of Health Carlos III, Spain)
Workshop Working Group III

*Transfer of research results into the market: How to optimize a safe, fast and economic process to implement Personalised Medicine (PM) approaches?*

**Leading questions:**

1. Technological challenges for Personalised Medicine research. Data generation and analysis.
3. Which issues related to market and regulation have to be addressed first in order to facilitate market access of Personalised Medicine approaches?
4. Entrepreneurial challenges common to all the previous questions.
Workshop Working Group IV

“Personalised medicine in the health system: How to ensure sustainability and an effective collaboration between all health care players as well as with prevention services?”

• Chair: Prof Dr Avi Israeli (CSO, Ministry of Health, Israel)

• Vice-chair: Dr Ricardo Pereira (Foundation for Science and Technology, Portugal)

• Rapporteur: Dr Toni Andreu (EATRIS-ERIC, The Netherlands)

• Vice-rapporteur: Cristina Nieto (National Institute of Health Carlos III, Spain)
Workshop Working Group IV
“Personalised medicine in the health system: How to ensure sustainability and an effective collaboration between all health care players as well as with prevention services?”

Leading questions:
1. What institutional design is required to successfully meet the expectations put by the Personalised Medicine paradigm?
2. What needs to be considered at the patient/population level?
3. How to translate scientific knowledge into Patient-Targeted Interventions?
Working procedure:

- Previously to the 2\textsuperscript{nd} ICPERMed Workshop, the Panel of each Working Group have elaborated a document to present the leading questions that will be discussed in the Working Groups’ parallel sessions.

- After validation by the Steering Board, these documents have been sent to the Workshop Working Groups participants before the workshop to assure an active participation, being able to prepare in advance their inputs for the discussion.
Working procedure:

- Each Working Group will have a parallel session for discussion of the leading questions proposed by each Panel of the WGs.

- The experts participating in each WG must provide inputs and participate actively in the discussion.

- The Panels will collect the main ideas of the WG discussion and will present them in the Plenary Session 3: Report on intermediate progress of each Working Group.
Working procedure:

- Each Working Group will have another parallel session for discussion of the leading questions proposed by each Panel of the WGs and will progress to achieve consensus and recommendations.

- The experts participating in each WG must provide inputs and participate actively in the discussion.

- The Panels will present the outcomes and summary of the discussion of the WG and the recommendations achieved in the **Plenary Session 4.1**: Final report of each Working Group.
Working procedure:

After the 2\textsuperscript{nd} ICPERMed Workshop, the Panels of each Working Group will elaborate the following documents:

- **Progress Consensus Report**: outcomes and executive summary of key and other recommendations achieved within the Working Groups’ discussion.

- **Final Consensus Report**: outcomes and synthetic summary of key and other recommendations compiling the Working Groups’ reports fed with Audience’s input.
Thank you for your attention!

Contact: Maria Cristina Nieto Garcia, PhD <mnieto@isciii.es>